Kurzfassung

A Phase 2, multicenter, open-label study to assess the safety, tolerability and pharmacokinetics of Apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis
Apremilast ("Otezla") pedriatric study